These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 1578749)

  • 21. Optimal therapeutic regimen of famotidine based on plasma concentrations in patients with chronic renal failure.
    Hachisu T; Yokoyama T; Oda Y; Ando K; Hattori Y; Yoshida T
    Clin Ther; 1988; 10(6):656-63. PubMed ID: 2905936
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis.
    Eriksson T; Höglund P; Turesson I; Waage A; Don BR; Vu J; Scheffler M; Kaysen GA
    J Pharm Pharmacol; 2003 Dec; 55(12):1701-6. PubMed ID: 14738599
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Protracted action of vecuronium in a patient with chronic renal insufficiency treated by dialysis].
    Hackl W; Plainer B; Mauritz W
    Anaesthesist; 1988 Sep; 37(9):598-600. PubMed ID: 2903692
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Pharmacokinetics of gadolinium-DTPA in chronic renal insufficiency requiring dialysis].
    Krahe T; Götz R; Lackner K; Haustein J; Klemenz U; Landwehr P; Heidbreder E; Schuhmann-Giampieri G
    Rofo; 1992 Jun; 156(6):523-6. PubMed ID: 1617171
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Meds and the dialysis patient.
    King B
    RN; 2000 Jul; 63(7):54-9; quiz 60. PubMed ID: 10983169
    [No Abstract]   [Full Text] [Related]  

  • 26. [Digoxon or digitoxin in patients with terminal kidney insufficiency in the dialysis stage?].
    Risler T; Peters U; Grabensee B; Fritsch WP; Hausamen TU; Grosse-Brockhoff F
    Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():1662-4. PubMed ID: 611905
    [No Abstract]   [Full Text] [Related]  

  • 27. Methylprednisolone pharmacokinetics and pharmacodynamics in chronic renal failure.
    Jusko WJ; Milad MA; Ludwig EA; Lew KH; Kohli RK
    Clin Nephrol; 1995 Jan; 43 Suppl 1():S16-9. PubMed ID: 7781199
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical results and pharmacokinetics of sorafenib in chronic hemodialysis patients with metastatic renal cell carcinoma in a single center.
    Kennoki T; Kondo T; Kimata N; Murakami J; Ishimori I; Nakazawa H; Hashimoto Y; Kobayashi H; Iizuka J; Takagi T; Yoshida K; Tanabe K
    Jpn J Clin Oncol; 2011 May; 41(5):647-55. PubMed ID: 21367805
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does haemodialysis significantly affect serum linezolid concentrations in critically ill patients with renal failure? A pilot investigation.
    Fiaccadori E; Maggiore U; Rotelli C; Giacosa R; Parenti E; Picetti E; Manini P; Andreoli R; Cabassi A
    Nephrol Dial Transplant; 2006 May; 21(5):1402-6. PubMed ID: 16504979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Laboratory assays in renal failure: therapeutic drug monitoring.
    Fissell WH
    Semin Dial; 2014; 27(6):614-7. PubMed ID: 24995571
    [No Abstract]   [Full Text] [Related]  

  • 31. [Alcohol intake in dialysis patients].
    Kanazawa Y; Nakao T
    Nihon Rinsho; 1992 Jan; 50 Suppl():974-9. PubMed ID: 1578797
    [No Abstract]   [Full Text] [Related]  

  • 32. Drug pharmacokinetics in patients with renal failure.
    Franson TR; Sorensen ET
    IMJ Ill Med J; 1978 Feb; 153(2):111-6. PubMed ID: 24023
    [No Abstract]   [Full Text] [Related]  

  • 33. Supplementary dose after hemodialysis.
    Keller F; Offermann G; Lode H
    Nephron; 1982; 30(3):220-7. PubMed ID: 7099332
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of renal failure on the pharmacokinetics of acyclovir.
    Laskin OL; Longstreth JA; Whelton A; Krasny HC; Keeney RE; Rocco L; Lietman PS
    Am J Med; 1982 Jul; 73(1A):197-201. PubMed ID: 7102702
    [No Abstract]   [Full Text] [Related]  

  • 35. Pharmacokinetics of human and recombinant leukocyte interferon in patients with chronic renal failure who are undergoing hemodialysis.
    Hirsch MS; Tolkoff-Rubin NE; Kelly AP; Rubin RH
    J Infect Dis; 1983 Aug; 148(2):335. PubMed ID: 6886494
    [No Abstract]   [Full Text] [Related]  

  • 36. The final word.
    La Greca G; Klinkmann H; Valderrábano F; Zucchelli P
    Kidney Int Suppl; 2000 Aug; 76():S156-9. PubMed ID: 10936813
    [No Abstract]   [Full Text] [Related]  

  • 37. Zinc supplementation in renal patients.
    O'Nion JV; Thor E; Ogilvie S
    Am J Clin Nutr; 1980 Oct; 33(10):2220-1. PubMed ID: 7424817
    [No Abstract]   [Full Text] [Related]  

  • 38. Pharmacokinetics of netivudine in haemodialysis patients.
    Le Roy F; Godin M; Legallicler B; Fillastre JP; Bidault R; Posner J; Peck RW
    J Antimicrob Chemother; 1996 Nov; 38(5):913-5. PubMed ID: 8961067
    [No Abstract]   [Full Text] [Related]  

  • 39. Accumulation of taurine in patients with renal failure.
    Suliman ME; Bárány P; Filho JC; Lindholm B; Bergström J
    Nephrol Dial Transplant; 2002 Mar; 17(3):528-9. PubMed ID: 11865115
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical pharmacokinetics 1990.
    Matzke GR; St Peter WL
    Clin Pharmacokinet; 1990 Jan; 18(1):1-19. PubMed ID: 2178847
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.